Aristotle University Of Thessaloniki (AUTH)
Συσχέτιση πολυμορφισμών του προαγωγέα του γονιδίου του παράγοντα νέκρωσης όγκων-α και της εξέλιξης του πολλαπλού μυελώματος σε ασθενείς υπό θεραπεία με θαλιδομίδη και ανάλογά της
Abstract
dc:descriptionThe aim of this study was to explore the association of TNF-a gene promoter polymorphisms -308 (G/A) and -238 (G/A) with the development of MM and clinical outcome in patients who were treated with thalidomide or its analogues. From January 2007 to November 2009, 57 patients were studied. Levels of TNF-α, IL-1β, IL-6 and VEGF were measured by enzyme immunoassays, in bone marrow and serum samples. DNA was extracted with a spin column method and real-time PCR was performed for the detection of gene polymorphisms and the melting curve analysis of the PCR product. 101 blood donors were used as a control group. Treatment was interrupted in 9/57 patients. 48/57 patients were evaluated for the treatment outcome. Thalidomide was received from 17/48 patients and lenalidomide from 31/48. Statistical analysis was performed using statistical packages SPSS 17.0 and STATA 11.0. The frequency of -308(G/A) polymorphism was 1.8% (GA) in patients and 17.8% (GA+ΑΑ) in healthy controls and the frequency of allele Α was 0.9% and 9.4%, respectively, a difference which was statistically significant (p=0.012). This fact suggests that, the presence of TNF-α-308 polymorphism is probably associated with a reduced risk for developing MM, having possibly a protective effect. The frequency of -238(G/A) polymorphism was 7% (GA) in patients and 5.9% (GA) in healthy controls, while the frequency of allele Α was 3.5% and 3%, respectively, a difference not statistically significant (p>0.05). Therefore, the presence of TNF-α-238(G/A) polymorphism cannot be considered as a risk factor in developing MM. As far as the association of the presence of -238(G/A) and the clinical outcome is concerned, Progressive/stable disease was established in 19 homozygotes and 2 heterozygotes, while Response was established in 26 and 1 respectively, a difference not statistically significant (p>0.05). PFS and OS did not differ significantly in homozygotes and heterozygotes (p>0.05). As a conclusion, in this research the prognostic value of -238G/A polymorphism of TNF-α in the outcome of treatment, with thalidomide or its analogues, and the progression of MM has not been established. There has not been evidence of any correlation of -308G/A and -238G/A polymorphisms of TNF-α with the levels of cytokines TNF-α, IL-1β, IL-6, VEGF in bone marrow and serum samples or/and the type of MM or/and the production of κ and λ light free chains (sFLC).
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2010
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kazila, Polyzo
- Καζήλα, Πολύζω
Subjects
dc:subject × 22- Πολυμορφισμός-308
- Πολυμορφισμός-238
- Παράγοντας νέκρωσης όγκων-α
- Πολλαπλούν μυέλωμα
- Θαλμιδομίδη
- Λεναλιδομίδη
- Θεραπεία
- Ολική επιβίωση
- Επιβίωση χωρίς πρόοδο της νόσου
- Polymorphism-308
- Polymorphism-238
- Tumor necrosis factor-a (TNF-α)
- Multiple myeloma
- Thalidomide
- Lenalidomide
- Treatment
- Overall survival ( OS)
- Progression-free survival
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες Υγείας
- Medical and Health Sciences
- Health Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/22075